TY - JOUR T1 - Determining factors for pertussis vaccination policy: A study in 5 EU countries JF - medRxiv DO - 10.1101/2019.12.11.19014449 SP - 2019.12.11.19014449 AU - Anabelle Wong AU - Annick Opinel AU - Simon Jean-Baptiste Combes AU - Julie Toubiana AU - Sylvain Brisse Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/15/2019.12.11.19014449.abstract N2 - Pertussis vaccination policy varies across Europe, not only in the type of vaccine – whole cell (wP) vs. acellular (aP1/2/3/5) – but also in the schedule and recommendation for parents. This study aims to investigate the determining factors for the type of vaccine, immunization schedule and maternal immunization recommendation. From March to May 2019, experts in national health agencies and major academic or research institutions from Denmark, France, Poland, Sweden and the UK were invited to a semi-structured interview. Thematic analysis was performed on the transcripts using a codebook formulated by 3 coders. Inter-coder agreement was assessed. Fifteen expert interviews were conducted. The identified driving factors for pertussis vaccine policy were classified into three domains: scientific factors, sociological factors, and pragmatic factors. The determining factors for the type of vaccine were prescriber’s preference, concern of adverse events following immunization (AEFI), effectiveness, and consideration of other vaccine components in combined vaccines. The determining factors for infant schedule were immunity response and the potential to improve coverage and timeliness. The determining factors for maternal immunization were infant mortality and public acceptability. To conclude, socio-political and pragmatic factors were, besides scientific factors, important in determining the vaccine type, schedule of childhood immunization and recommendations for parents.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the INCEPTION interdisciplinary project at Institut Pasteur, "Understanding whooping cough resurgence in Europe by combing genomic, epidemiological and sociological approaches" (French Government Investissements d’Avenir grant ANR-16-CONV-0005).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available and archived; transcripts details are not to be published due to confidentiality agreement. ER -